1. Global Market Leadership (Q2 2026) ​Top 3 Global Players: Johnson & Johnson leads with $25.31B (+6.6% YoY), followed closely by Eli Lilly at $23.00B (+48.0% YoY) and AbbVie at $16.99B (+6.6% YoY). ​Massive Growth Drivers: Eli Lilly surged +48% YoY, driven by strong demand for obesity and diabetes treatments like Mounjaro and Zepbound. Eli Lilly also raised its 2026 revenue guidance to $85B–$87B. ​2. Indian Pharma Landscape (Q1 FY2026–27) ​Top Performers: Sun Pharma leads the Indian market with ₹15,299.9 Cr (+10.5% YoY), followed by Aurobindo Pharma at ₹9,150.4 Cr (+16.3% YoY) and Lupin at ₹8,276.9 Cr (+32.0% YoY). ​Profitability Highlights: ​Sun Pharma: Net profit surged to ₹2,894.8 Cr (+27% YoY), with specialty medicine sales reaching $351M (21.9% of total revenue). ​Lupin: Recorded a +33.3% YoY sales surge with EBITDA up +42.8% (31.4% EBITDA margin). ​Zydus: Grew revenue by +22% YoY to ₹8,017 Cr, though net profit fell ~36% due to higher operational costs. ​3. Focus Segment: Ophthalmic (Eye-Care) Market ​Global Leaders: Roche leads global ophthalmic revenue at $5.07B, followed by Bayer ($3.52B) and AbbVie ($2.11B). ​India Growth Outlook: The Indian ophthalmic drugs market is projected to expand from $253.1M in 2025 to $333M by 2030. ​Growth Drivers: Driven by higher eye disease prevalence, increased diagnosis/awareness, and rapid adoption of innovative therapies. ​4. Key Strategic Growth Drivers Across the Industry ​Metabolic Therapies: High demand for obesity and diabetes care globally. ​Specialty & Oncology: Specialty medicines and oncology/immunology expansion are driving higher margins. ​Supply Chain & Infrastructure: Heavy investments in global manufacturing expansion (e.g., Lilly’s $4.5B Indiana expansion commitment). ​Domestic & Export Strength: Balanced growth across Indian domestic formulations and key international markets.